Navigation Links
Cambrex Reports Fourth Quarter And Full Year 2012 Financial Results
Date:2/6/2013

– Continuing Operations," including the Company's expectation that full year 2013 sales, excluding the impact of foreign currency, will increase between 8% and 12% versus 2012, that full year 2013 EBITDA will be between $62 and $68 million, that capital expenditures will be approximately $36 to $40 million and that depreciation will be $22 to $24 million in 2013.  These and other forward looking statements may be identified by the fact that they use words such as "expects," "anticipates," "intends," "estimates," "believes" or similar expressions.  Any forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations.  The factors described in Item 1A of Part I of the Company's Annual Report on Form 10-K for the period ended December 31, 2011, captioned "Risk Factors," or otherwise described in the Company's filings with the SEC, as well as any cautionary language in the Company's Annual Report on Form 10-K for the period ended December 31, 2011, provide examples of such risks and uncertainties that may cause the Company's actual results to differ materially from the expectations the Company describes in its forward-looking statements, including, but not limited to, pharmaceutical outsourcing trends, competitive pricing or product developments, governmental legislation and regulations (particularly environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation disclosed in the Company's public filings, changes in foreign exchange rates, uncollectible receivables, loss on disposition of assets, cancellations or delays in renewal of contracts, lack of suitable raw materials or packaging materials, and the Company's ability to receive regulatory approvals for its products, as well as risks relating to a Phase 3 supply agreeme
'/>"/>
SOURCE Cambrex Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Cambrex Reports First Quarter 2012 Results
2. Cambrex To Present At Jefferies 2012 Global Healthcare Conference
3. Cambrex Announces Significant New Supply Agreement
4. Cambrex to Announce Third Quarter 2012 Financial Results on October 31, 2012
5. Cambrex Reports Third Quarter 2012 Financial Results
6. Cambrex To Announce Fourth Quarter 2012 Financial Results On February 6, 2013
7. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
8. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
9. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
10. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
11. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... CARDIFF-BY-THE-SEA, Calif. , Dec. 19, 2014 ... ;  Sorrento), an oncology company developing new treatments ... a privately-held immuno-oncology company developing proprietary Neukoplast ® ... therapy, announced today that the companies have entered ... generation CAR-TNK™ (pronounced as "Car-Tank") immunotherapies for the ...
(Date:12/19/2014)... Dec. 18, 2014 Research and Markets ... of the "Micro Market Monitor: North American ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... progressing steadily, which has resulted in fueling the ... The main purpose of these dermatology devices is ...
(Date:12/19/2014)... Capnia, Inc. (NASDAQ: CAPN ... based on its proprietary Sensalyze™ Technology Platform for ... results for the third quarter and nine months ... completion of our initial public offering (IPO), we ... initiated CoSense® commercial launch," said Anish Bhatnagar, M.D., ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8
... 2011 Cumberland Pharmaceuticals Inc. (Nasdaq: ... care and gastroenterology markets, today announced fourth quarter and full ... For the three months ended December 31, 2010, net revenue ... corresponding period in 2009. This quarterly revenue growth was largely ...
... Hill-Rom Holdings, Inc. (NYSE: HRC ) today ... immediately. "I am pleased to have someone of ... Mark Guinan, Senior Vice President and Chief Financial Officer of ... will contribute to the solid financial leadership of our company ...
Cached Medicine Technology:Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 2Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 3Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 4Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 5Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 6Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 7Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 8Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 9Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 10Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 11Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 12Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 13
(Date:12/19/2014)... (PRWEB) December 19, 2014 Diet Doc ... date, current approach to weight loss by ... understanding. The professionals at the company understand that remaining ... side effects of eliminating carbohydrates and sugars from the ... tempted to abandon their weight loss goals. , ...
(Date:12/19/2014)... The global magnetic resonance imaging (MRI) ... is saturated with numerous players developing innovative technologies. ... as non-invasive nature, MRI systems have seen continued ... healthcare market. Rapid advances in the field imaging ... have greatly expanded the potential of therapeutic applications. ...
(Date:12/19/2014)... 19, 2014 If you have ever ... breathing, you probably wished you had an arsenal of ... cystic fibrosis, and other breathing disorders. Currently, the only ... avoiding triggers, but other common treatments do exist. ... in San Antonio, TX, 34 asthma educators responded to ...
(Date:12/19/2014)... 19, 2014 This is a professional ... global Gliquidone industry with a focus on the Chinese ... status of the Gliquidone manufacturers and is a valuable ... interested in the industry. , Firstly, the report provides ... applications and manufacturing technology. Then, the report explores the ...
(Date:12/19/2014)... 2014 (HealthDay News) -- A new study suggests a ... severe hot flashes and night sweats -- and higher ... flashes are common during menopause, affecting about 60 percent ... women after menopause, since they then face a higher ... suggest women who exhibit moderate or severe menopausal symptoms ...
Breaking Medicine News(10 mins):Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 2Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 3Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 4Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 2Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 3Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 4Health News:Harmonica Techs, Inventors of the Pulmonica®, Unveil New Findings on Complementary Treatments for Asthma 2Health News:Harmonica Techs, Inventors of the Pulmonica®, Unveil New Findings on Complementary Treatments for Asthma 3Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 2Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 3Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 4Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 5Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 6Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2
... new study has shown that vision correction patients will ... Lasek surgery. Both types of surgeries are equally safe ... cut flaps in the cornea and rectify the shape. ... surface of the cornea. This helps in doing away ...
... report has suggested that Thursday may not be a good day ... might end up waiting longer in the hospital.// ,The ... the trend for five years have blamed the procedures in the ... requirements, as it is thought to be. ,It was ...
... have been warned about a potential hepatitis risk for those ... ,Authorities suspect that those who consumed food from McDonald's ... of contracting Hepatitis A. The medical officer confirmed that a ... was suffering the highly infectious stage of the virus. It ...
... million U.S. dollars to take the anti-bird flu initiative forward, in ... for 2007 as// compared to the spending allocated in 2006. ... bird flu control, Bayu Krishnamurthi, the added spending on bird flu ... drive. So far there have been 74 human cases of bird ...
... by scientists, promises protection against all strains of flu virus. It ... influenza A virus, that is the cause of outbreaks of both ... vaccine is expected to bestow life long immunity. The only other ... every year. ,The injection is yet to be ...
... Highly developed nations like the U.S, with a fast paced lifestyle ... of saturated fat which can cause an// avalanche of diseases. ... eat more and put on more weight, proves a recent ... adults who live with children that those who live without children ...
Cached Medicine News:
... Merocel Ophthalmic Products provide ... fiber free products for ... safe cleaning of fine ... Merocel material is highly ...
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Medicine Products: